Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES FYNDIQ IN CONNECTION WITH INVESTMENT BY NORTHZONE AND INDUSTRIFONDEN
Mandate

VINGE ADVISES FYNDIQ IN CONNECTION WITH INVESTMENT BY NORTHZONE AND INDUSTRIFONDEN

November 07, 2014

Vinge has advised Fyndiq in connection with the company’s capital raising of SEK 150 million from Northzone and Industrifonden. Fyndiq (www.fyndiq.se) is an online shopping site linking e-traders and consumers. Since the company was formed in 2010, it has helped thousands of e-traders to sell their products to millions of consumers.

Vinge’s team consisted of responsible partner Jonas Bergström together with, among others, associates Joacim Rydergård, Gustav Jönsson, Ulrika Andersson and Andrea Jägerstad as well as paralegal Pernilla Warg.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026